Helixmith Obtains Domestic Patent for ADHD Treatment and Improvement Candidate Substance 'HX106'

[Asia Economy Reporter Lee Gwan-joo] Helixmith announced on the 3rd that it has obtained a domestic patent for ‘HX106,’ a candidate substance for the treatment and improvement of Attention Deficit Hyperactivity Disorder (ADHD).

HX106 inhibits the overactivation of glutamate receptors, which are known to cause ADHD. In particular, when combined with the representative treatment methylphenidate, it significantly improves attention deficits and hyperactivity in children with ADHD compared to the group taking methylphenidate alone. Based on fMRI test results showing improved connectivity in brain regions related to attention control, this patent was granted. Accordingly, HX106 is expected to be usefully applied as a combination therapy or an improvement food for ADHD.

HX106 is a plant-based complex extract developed by Helixmith’s natural products research team. Its efficacy in improving working memory was proven, and it was approved as a individually recognized ingredient by the Ministry of Food and Drug Safety in 2015. Additionally, its efficacy as a treatment and improvement substance for ADHD was published in the international journals Neutrients in 2020 and Integrative Medicine Research in 2021. The material’s safety was also recognized through NDI (New Dietary Ingredients) certification by the U.S. FDA.

ADHD is a neuropsychiatric disorder caused by abnormalities in the frontal lobe, leading to difficulties in behavior, cognition, and emotion. Its main symptoms include inattention, hyperactivity, and impulsivity. It primarily appears in childhood, and if not properly managed during growth, it increases the risk of various disorders such as tic disorder, obsessive-compulsive disorder, learning disabilities, and depression. In South Korea, three treatments?methylphenidate, atomoxetine, and clonidine?are used to improve symptoms, but various side effects such as insomnia, loss of appetite, cardiovascular problems, and delayed growth in children have been reported.

Yoo Seung-shin, CEO of Helixmith, said, “Currently used ADHD medications have limited effectiveness and sometimes cause side effects. HX106 is composed of plant materials whose safety has been proven not only in Korea but also in the United States. Given that it has been recognized as an ADHD treatment substance in this patent, expectations are high.”

This content was produced with the assistance of AI translation services.